PMID- 21660144
OWN - NLM
STAT- MEDLINE
DCOM- 20111003
LR  - 20240317
IS  - 1110-7251 (Electronic)
IS  - 1110-7243 (Print)
IS  - 1110-7243 (Linking)
VI  - 2011
DP  - 2011
TI  - Gefitinib in non small cell lung cancer.
PG  - 815269
LID - 10.1155/2011/815269 [doi]
LID - 815269
AB  - Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth 
      factor receptor (EGFR) that plays a key role in the biology of non small cell 
      lung cancer (NSCLC). Phase I studies indicated that the recommended dose of 
      gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most common adverse 
      events. The positive results obtained in early phase 2 clinical trials with 
      gefitinib were not confirmed in large phase 3 trials in unselected patients with 
      advanced NSCLC. The subsequent discovery that the presence of somatic mutations 
      in the kinase domain of EGFR strongly correlates with increased responsiveness to 
      EGFR tyrosine kinase inhibitors prompted phase 2 and 3 trials with gefitinib in 
      the first line-treatment of EGFR-mutated NSCLC. The results of these trials have 
      demonstrated the efficacy of gefitinib that can be now considered as the standard 
      first-line treatment of patients with advanced NSCLC harbouring activating EGFR 
      mutations.
FAU - Costanzo, Raffaele
AU  - Costanzo R
AD  - Medical Oncology Unit, Thoraco-Pulmonary Department, National Cancer Institute, 
      80131 Napoli, Italy.
FAU - Piccirillo, Maria Carmela
AU  - Piccirillo MC
FAU - Sandomenico, Claudia
AU  - Sandomenico C
FAU - Carillio, Guido
AU  - Carillio G
FAU - Montanino, Agnese
AU  - Montanino A
FAU - Daniele, Gennaro
AU  - Daniele G
FAU - Giordano, Pasqualina
AU  - Giordano P
FAU - Bryce, Jane
AU  - Bryce J
FAU - De Feo, Gianfranco
AU  - De Feo G
FAU - Di Maio, Massimo
AU  - Di Maio M
FAU - Rocco, Gaetano
AU  - Rocco G
FAU - Normanno, Nicola
AU  - Normanno N
FAU - Perrone, Francesco
AU  - Perrone F
FAU - Morabito, Alessandro
AU  - Morabito A
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110523
PL  - United States
TA  - J Biomed Biotechnol
JT  - Journal of biomedicine & biotechnology
JID - 101135740
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinazolines)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - S65743JHBS (Gefitinib)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - ErbB Receptors/*antagonists & inhibitors/genetics/therapeutic use
MH  - Gefitinib
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Mutation
MH  - Protein Kinase Inhibitors/adverse effects/*therapeutic use
MH  - Quinazolines/*adverse effects/*therapeutic use
PMC - PMC3110340
EDAT- 2011/06/11 06:00
MHDA- 2011/10/04 06:00
PMCR- 2011/05/23
CRDT- 2011/06/11 06:00
PHST- 2010/12/17 00:00 [received]
PHST- 2011/03/15 00:00 [accepted]
PHST- 2011/06/11 06:00 [entrez]
PHST- 2011/06/11 06:00 [pubmed]
PHST- 2011/10/04 06:00 [medline]
PHST- 2011/05/23 00:00 [pmc-release]
AID - 10.1155/2011/815269 [doi]
PST - ppublish
SO  - J Biomed Biotechnol. 2011;2011:815269. doi: 10.1155/2011/815269. Epub 2011 May 
      23.